David D. Pendergast
Plus aucun poste en cours
Profil
David D.
Pendergast is the founder of Proteostasis Therapeutics, Inc. which was founded in 2006, where he held the title of Chief Executive Officer from 2006 to 2011.
He also held the position of Executive Chairman & Chief Executive Officer at Altus Pharmaceuticals, Inc. in 2008.
Dr. Pendergast's former jobs include Vice President-Product Development & Quality at Biogen MA, Inc. from 1996 to 2001, Principal at The Upjohn Co. and Fisons Plc, and Chief Operating & Executive Officer at Transkaryotic Therapies, Inc. He was also President-Human Genetic Therapies at Shire Plc from 2005 to 2007 and at Shire Acquisition, Inc. from 2005 to 2008.
Dr. Pendergast's education history includes a graduate and doctorate degree from the University of Wisconsin and an undergraduate degree from Western Michigan University.
Anciens postes connus de David D. Pendergast
| Sociétés | Poste | Fin |
|---|---|---|
| PROTEOSTASIS THERAPEUTICS, INC. | Directeur Général | 20/10/2011 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Directeur Général | 30/05/2008 |
Shire Acquisition, Inc.
 Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Corporate Officer/Principal | 12/03/2008 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/12/2007 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/08/2001 |
Formation de David D. Pendergast
| Western Michigan University | Undergraduate Degree |
| University of Wisconsin | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Fisons Plc
 Fisons Plc Pharmaceuticals: OtherHealth Technology Fisons Plc Manufactured and supplied ethical and proprietary medicines, veterinary products, laboratory and educational scientific equipment, clinical diagnostic supplies and garden products. The company was headquartered in Ipswichm the United Kingdom. | Health Technology |
| The Upjohn Co. | Health Technology |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Health Technology |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |